|
|
|
|
|
|
2C-B |
|
|
On December 20, 1994, in a notice of proposed
rulemaking published in the Federal Register (59 FR 65521) and after a
review of relevant data, the Deputy Administrator of the DEA proposed to
place 4-bromo-2,5-DMPEA into Schedule I making 2C-B illegal in the
United States. This became permanent law July, 2 1995. Prior to this,
2C-B was commercially available as an aphrodisiac under the tradename
"Eros" which was manufactured by the German phamaceutical company
Drittewelle. Recently 2C-B has been distributed under the street name
"Nexus." In the past 2C-B has also been distributed as "Eve", "Venus",
"Bees", and (incorrectly) "bromo-mescaline." Internationally, 2C-B is a
Schedule II drug under the Convention on Psychotropic Substances[1]. 2C-B is a psychedelic hallucinogenic drug first synthesized by Alexander Shulgin in 1974, sometimes used as an entheogen. The full name of the chemical is 4-bromo-2,5-dimethoxyphenethylamine. In his book PIHKAL (Phenethylamines I Have Known and Loved), Shulgin lists the dosage range as 16 to 24 mg. 2C-B is a white powder usually found in pressed tablets or gel caps, and is almost always taken orally. Snorting is also an effective, though extremely painful, way to ingest the drug.
InterventionGuide.com Articles
|
|